Tue, May 13, 8:28 PM (30 days ago)
**Hyperfine, Inc. (HYPR) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $2.1 million, down 35.1% YoY due to decreased device sales (43.7% drop) partially offset by increased service sales (4.1% rise). - **Gross Margin:** $883,000, down 34.8% YoY, reflecting the decrease in revenue. - **Operating Expenses:** $11.8 million, down 1.8% YoY, with R&D expenses decreasing 9.6% and G&A expenses down 5.0%, but sales and marketing expenses up 26.7%. - **Net Loss:** $9.4 million, slightly improved (4.4% decrease) from the $9.8 million loss in Q1 2024. - **Cash Flow:** Negative operating cash flow of $9.2 million, improved from the $12.5 million negative cash flow in Q1 2024. Financing activities provided $5.6 million, mainly from equity offerings. **Key Metrics and Trends:** - **Device Sales:** 6 units sold in Q1 2025, down from 13 units in Q1 2024. - **Cash Position:** $33.1 million in cash and cash equivalents as of March 31, 2025. - **Equity Financing:** Raised $6.0 million in a registered direct offering and $1.0 million through an ATM program. **Uncertainties and Future Operations:** - **Market Risks:** Exposure to interest rate, inflation, and foreign exchange risks, though currently managed. - **Regulatory:** Received FDA clearance for the ninth-generation AI-powered Swoop® system software and CE Mark and UKCA Mark approvals for international expansion. - **Funding:** Continued reliance on equity financing to support operations and growth. - **Stock Listing:** Received notice from Nasdaq regarding non-compliance with the minimum bid price requirement, with a compliance period until October 27, 2025. **Future Outlook:** - **Commercialization:** Expanding sales in international markets and broadening the range of clinical uses for the Swoop® system. - **Technical Innovation:** Continuous improvement of AI-powered image quality and exploration of new imaging applications. - **Grant Funding:** Ongoing support from the Bill & Melinda Gates Foundation for global health initiatives. **Conclusion:** Hyperfine, Inc. faces challenges in maintaining revenue growth and managing cash burn, but strategic initiatives in commercialization, technical innovation, and international expansion aim to drive future success. The company's financial health remains dependent on continued equity financing and successful execution of its growth strategies.